中央型临床I期非小细胞肺癌首选肺叶切除术而非亚肺叶切除
该回顾性研究纳入719例I期非小细胞肺癌患者,按肿瘤位置分析生物学行为,比较肺叶切除与更广泛切除的生存。中央型占17.2%,其代谢更高、腺癌分级更高、淋巴结转移更频繁;中央型和影像纯实性为隐匿性淋巴结转移的显著因素;生存无位置差异。结论:中央型临床I期NSCLC宜行肺叶切除。
要点
- 中央型临床I期NSCLC代谢更高且淋巴结转移风险更高。
- 中央型和影像纯实性肿瘤是隐匿性淋巴结转移的显著因素。
- 中央型临床I期NSCLC肺叶切除可能是更佳治疗选择。
核心结论
- 中央型临床I期NSCLC倾向高代谢并潜在淋巴结转移风险,肺叶切除可能是更佳治疗选择。
研究设计与样本
- 回顾性研究纳入719例2004年4月至2023年12月接受根治性手术的I期NSCLC患者。
- 按肿瘤位置分析生物学行为,并评估不同位置下肺叶切除或更广泛切除(含肺门和纵隔淋巴结清扫)的总生存和无复发生存。
主要发现
- 中央型组124例(17.2%),周围型组595例(82.8%)。
- 中央型组PET/CT的标准化摄取最大值显著更高、腺癌亚型分级更高、淋巴结转移频率更高。
- 多因素分析中,中央型和影像纯实性肿瘤(实变/肿瘤比=1)为隐匿性淋巴结转移的显著因素。
- 基于肿瘤位置的生存无显著差异。
临床怎么用
- 对中央型临床I期NSCLC,优先考虑肺叶切除而非亚肺叶切除。
- 中央型或影像纯实性肿瘤应警惕隐匿性淋巴结转移,需规范淋巴结清扫。
局限性
- 回顾性研究设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Tumour location can affect clinicians' decisions regarding the surgical procedure, especially when choosing between lobectomy and segmentectomy. The biological behaviour of clinical stage I non-small cell lung cancer (NSCLC) may differ based on tumour location. We aimed to explore the biological behaviour of centrally located (CL) clinical stage I NSCLC and to identify which surgical procedure is more appropriate for such tumours. METHODS: This retrospective study included 719 patients who underwent curative operations for stage I NSCLC between April 2004 and December 2023. The biological behaviour of the tumours was analysed based on tumour location. Overall and recurrence-free survivals in patients who underwent lobectomy or more extensive procedures, including hilar and mediastinal lymph node dissection, were assessed based on tumour location. RESULTS: A total of 124 (17.2%) and 595 (82.8%) patients were included in the CL and peripherally located groups, respectively. The CL group had a significantly higher standardized uptake value maximum on positron emission tomography/computed tomography, a higher-grade adenocarcinoma subtype, and a higher frequency of lymph node metastasis than the peripherally located group. In multivariable analysis, CL and radiologically pure solid tumours (consolidation/tumour ratio = 1) were significant factors for occult lymph node metastasis. No significant difference was observed in survival based on tumour location. CONCLUSIONS: Centrally located clinical stage I NSCLCs tend to be hypermetabolic and have a potential risk of lymph node metastasis. Lobectomy could be a better treatment option for CL clinical stage I NSCLC.
引用
- Takamori S, Nakatsuka M, Watanabe H, et al. Lobectomy is the preferred choice rather than sublobar resection for centrally located clinical stage 1 non-small cell lung cancer. Eur J Cardiothorac Surg. 2025. PMID: 40646687. doi:10.1093/ejcts/ezaf233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。